Key Insights

Highlights

Success Rate

86% trial completion

Published Results

18 trials with published results (21%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

8.2%

7 terminated out of 85 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

14%

12 trials in Phase 3/4

Results Transparency

43%

18 of 42 completed with results

Key Signals

18 with results86% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (19)
P 1 (2)
P 2 (10)
P 3 (11)
P 4 (1)

Trial Status

Completed42
Recruiting14
Unknown14
Terminated7
Active Not Recruiting5
Withdrawn2

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 42 completed trials

Clinical Trials (85)

Showing 20 of 20 trials
NCT05503030Active Not RecruitingPrimary

Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients

NCT06836414Not ApplicableWithdrawn

Lung Cancer Screening CT for Firefighters

NCT05722340Not ApplicableRecruitingPrimary

NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases

NCT04325217Active Not RecruitingPrimary

Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

NCT07473700Phase 2Not Yet Recruiting

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT05285982Phase 3CompletedPrimary

A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

NCT06572384Phase 3RecruitingPrimary

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06325696Phase 2Recruiting

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

NCT04559581CompletedPrimary

Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan

NCT07372989Phase 1RecruitingPrimary

Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease

NCT04707781RecruitingPrimary

Database for Interstitial Lung Disease

NCT05854563Recruiting

Cough Capture as a Portal Into the Lung

NCT05321082Phase 3CompletedPrimary

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

NCT06385301Not ApplicableCompleted

Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases

NCT05855109Completed

Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors

NCT00258583RecruitingPrimary

Dorothy P. and Richard P. Simmons Center for ILD Research Registry

NCT05151640CompletedPrimary

INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

NCT05492994Not ApplicableActive Not RecruitingPrimary

A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease

NCT02369575WithdrawnPrimary

Identification of Novel Markers of Human Lung Disease

NCT04283994Not ApplicableCompleted

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

Scroll to load more

Research Network

Activity Timeline